Skip to main content

Exploitation of genomic variants affecting coronary artery disease and stroke risk for therapeutic intervention

Objetivo

Atherosclerosis and its most disabling sequelae, coronary artery disease (CAD) and stroke, are leading causes of death in Europe. Until now, preventive and therapeutic interventions for these diseases aim at ameliorating the effects of established cardiovascular risk factors. More recently, results of genome-wide association (GWA) studies added to our perception of mechanisms leading to atherosclerosis. At present, over 40 CAD and several genomic risk loci have been identified, the majority through efforts led by the applicants. Some genes at these loci work through known risk factors such as lipids and, in fact, are already established or evolving treatment targets. However, this is not true for the majority of risk variants, which implies that key pathways leading to atherosclerosis are yet to be exploited for therapeutic intervention. This EU network (CVgenes@target), which brings together an equal number of SME- and academic partners, will utilize genomic variants affecting atherosclerosis risk for identification of both underlying genes and affected pathways in order to identify, characterize, and validate novel therapeutically relevant targets for prevention and treatment of CAD and stroke. In programme 1 we will investigate molecular mechanisms at the genomic loci in order to further unravel causal genes, in programme 2 we will explore in vitro and in vivo whether the pathways disturbed by causal genes are suitable for therapeutic intervention, and in programme 3 we will establish assays and initiate high throughput screens to tackle therapeutically attractive targets. Our resources including large OMICs and state-of-the-art bioinformatics platforms as well as multiple, already established in vitro and in vivo models support the feasibility of the approach. In fact, two genomic risk loci (ADAMTS7 (CAD); HDAC9 (stroke and CAD)), both identified in GWA studies under direction of the applicants, already revealed attractive targets for therapeutic intervention.

Convocatoria de propuestas

FP7-HEALTH-2013-INNOVATION-1
Consulte otros proyectos de esta convocatoria

Régimen de financiación

CP-FP - Small or medium-scale focused research project

Coordinador

DEUTSCHES HERZZENTRUM MUNCHEN
Dirección
Lazarettstrasse 36
80636 Munich
Alemania
Tipo de actividad
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Aportación de la UE
€ 853 354,30
Contacto administrativo
Per Larsen (Mr.)

Participantes (12)

UNIVERSITY OF LEICESTER
United Kingdom
Aportación de la UE
€ 825 270
Dirección
University Road
LE1 7RH Leicester
Tipo de actividad
Higher or Secondary Education Establishments
Contacto administrativo
Marie Adams (Mrs.)
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Alemania
Aportación de la UE
€ 503 040
Dirección
Geschwister Scholl Platz 1
80539 Muenchen
Tipo de actividad
Higher or Secondary Education Establishments
Contacto administrativo
Martin Dichgans (Prof.)
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
United Kingdom
Aportación de la UE
€ 354 560
Dirección
Wellington Square University Offices
OX1 2JD Oxford
Tipo de actividad
Higher or Secondary Education Establishments
Contacto administrativo
Stephen Conway (Dr.)
UNIVERSITAET zu LUEBECK
Alemania
Aportación de la UE
€ 336 080
Dirección
Ratzeburger Allee 160
23562 Lubeck
Tipo de actividad
Higher or Secondary Education Establishments
Contacto administrativo
Nadine Clausen (Dr.)
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Países Bajos
Aportación de la UE
€ 609 720
Dirección
Heidelberglaan 100
3584 CX Utrecht
Tipo de actividad
Higher or Secondary Education Establishments
Contacto administrativo
Karin Krol-Simons (Mrs.)
BIOCEROS BV

La participación finalizó

Países Bajos
Aportación de la UE
€ 282 763,20
Dirección
Yalelaan 46
3584 CM Utrecht
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contacto administrativo
Remco Brandt (Mr.)
European ScreeningPort GmbH
Alemania
Aportación de la UE
€ 60 836,50
Dirección
Schnackenburgallee
22525 Hamburg
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contacto administrativo
Philip Gribbon (Dr.)
CLINICAL GENE NETWORKS AB
Suecia
Aportación de la UE
€ 397 748,20
Dirección
Karolinska Sience Park - Fogdevreten 2
171 77 Stockholm
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contacto administrativo
Johan Björkegren (Prof.)
4SC DISCOVERY GMBH
Alemania
Aportación de la UE
€ 454 260
Dirección
Am Klopferspitz 19A
82152 Planegg Martinsried
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contacto administrativo
Stefan Strobl (Dr.)
GENEDATA AG
Suiza
Aportación de la UE
€ 374 062,50
Dirección
Margarethenstrasse 38
4053 Basel
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contacto administrativo
Timo Wittenberger (Dr.)
Horizon Discovery Limited
United Kingdom
Aportación de la UE
€ 240 179,20
Dirección
Cambridge Research Park
CB25 9TL Cambridge
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contacto administrativo
Dirk Gewert (Mr.)
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
Alemania
Aportación de la UE
€ 703 575,10
Dirección
Hansastrasse 27C
80686 Munchen
Tipo de actividad
Research Organisations
Contacto administrativo
Michael Prestele (Mr.)